ABT vs BSX — Key Metrics
| Metric | ABT (ABBOTT LABORATORIES) | BSX (BOSTON SCIENTIFIC CORP) |
|---|---|---|
| Price | 98.83 | 43.65 |
| Market Cap | 171.01 Billion | 63.26 Billion |
| P/E (TTM) | 31.88 | 17.53 |
| P/B (Quarterly) | 3.586 | 2.815 |
| P/S (TTM) | 3.67 | 3.01 |
| Net Profit Margin (TTM) | 11.6 | 17.5 |
| Gross Margin (TTM) | 56.6 | 69.9 |
| ROE (TTM) | 10.4 | 14.9 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
ABT · ABBOTT LABORATORIES
Outperform
BSX · BOSTON SCIENTIFIC CORP
Greatly Outperform
Recommendation Summary
Stock ABT is projected to outperform the market, stock BSX is projected to greatly outperform the market. Upfront Recommendation: BSX.
Financial Metrics
Prices delayed ~15 min
| ABT | Metrics | BSX |
|---|---|---|
| $98.83 | Price | $43.65 |
| — | Market Capitalization | — |
| 31.88 | Price to Earnings Ratio | 17.53 |
| 3.67 | Price to Sales | 3.01 |
| 21.86 | Price to FCF Ratio | 17.45 |
| 6.48 | Price to Gross Profit | 4.31 |
| 54.12 | Price to R&D | 29.38 |
| 6.98 | Price to Current Assets | 7.94 |